TZTaotao Zou

Taotao Zou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Taotao Zou has a total of 183 co-authors. Here are the top co-authors by number of shared publications:

  • Bei Cao

    College of Education Sciences

    19 shared publications
  • Chi-Ming Che

    Department of Chemistry HKU-CAS Joint Laboratory on New Materials and Shanghai-Hong Kong Joint Laboratory on Chemical Synthesis The University of Hong Kong Pokfulam Road, Hong Kong China

    19 shared publications
  • Xiaolin Xiong

    State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China

    14 shared publications
  • Moyi Liu

    State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China

    10 shared publications
  • Yuan Wang

    State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China

    10 shared publications
  • Albert S. C. Chan

    State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China

    9 shared publications

Latest Publications

  • Subcellular photochemistry for precision spatial protein targeting

    by Moyi Liu, Xiaolin Xiong, Ao Zhang, Taotao Zou

    Proteins with conserved active sites but distinct subcellular localizations, such as mislocalized variants, splicing isoforms and isozymes, are prevalent in disease. However, conventional drug design lacks the spatial control needed for their selective targeting. Subcellular photochemistry offers a solution. Light-activated catalysts with spatiotemporal control convert inert prodrugs into active drugs at the desired subcellular location, without affecting conserved proteins at native sites. In this Perspective, we discuss challenges of targeting mislocalized proteins, principles of subcellular photochemistry for site-specific intervention, strategies for anchoring photocatalysts and key examples of subcellular photocatalytic prodrug activation for precision targeting. We also examine limitations of this approach and propose future solutions. This strategy is expected to expand the druggable target repertoire and advance precision medicine.


  • Beyond Thiol-Enzyme Inhibition: Sterically Bulky NHC-Au(I) Complexes are Catalytically Active Anticancer Agents with Reprogrammed Immunomodulatory Function

    by Zhi Zhong, Haitao Liu, Qiong Wu, Bei Cao, Yujiao Peng, Moyi Liu, Liang-Mei Yang, Yue Lin, Ke-Bin Huang, Xiaolin Xiong, et al.

    Metallodrug-induced immunogenicity offers significant potential for improving the efficacy of cancer immunotherapy with metals such as gold serving as a notable example. However, heavy metals may concurrently disrupt immune cell function, and a few of them can augment immunogenicity without compromising immunological integrity. Here, we report sterically bulky Au(I) complexes as catalytically active anticancer agents with the capability to reprogram immunomodulatory function. Our initial studies identified complex IPr-Au-Cl, characterized by bulky substituents, which catalytically activated an alkyne probe in the presence of GSH and triggered hydride transfer from NADH to NAD+. Subsequent structural optimization led to the development of Au-8, which showed an increased catalytic activity and improved cytotoxicity against cancer cells. Although Au-8 induced elevated ROS levels and immunogenic CRT exposure in cancer cells akin to auranofin, it triggered unique proteomic responses, notably showing minimal inhibition of thioredoxin reductase 1 (TrxR1), a crucial protein for maintaining immune cell function. Auranofin's inhibition of TrxR1 resulted in immunosuppression at one-seventh of its cytotoxic IC50 against cancer cells. In contrast, Au-8 not only maintained but also enhanced immune function in vitro, ex vivo, and in vivo, including activated immunogenic phagocytosis and cytotoxic effects in human peripheral blood mononuclear cells isolated from healthy donors. This study, therefore, presents a novel design for gold compounds that leverages steric hindrance to achieve catalytic anticancer activity without affecting TrxR1, opening avenues for future gold-based therapeutics with desirable immunomodulatory effects.


  • Gold-Catalyzed Reactions of o -Alkynylarylaldehydes with Alkenes for the Synthesis of 3,4-Dihydronaphthalene Derivatives

    by Can Yang, Yan Yang, Moyi Liu, Hejiang Luo, Taotao Zou

    Herein, we report a selective synthesis of 3,4-dihydronaphthalene derivatives from o-quinodimethane (o-QDM) intermediates by gold(I). This method is achieved through [(BINAP)2Au2(BArF4)2]-catalyzed reactions of o-alkynylarylaldehydes with alkenes following 1,5-H migration. The reaction features a broad substrate scope and excellent functional group tolerance. Notably, the catalytic system was highly efficient at 0.1 mol % loading for most reactions, which could be reduced to 0.05 mol % in gram-scale reactions while maintaining the yield. More significantly, the reaction enables late-stage modification of complex molecules, providing a new strategy for drug derivatization and efficient synthesis of bioactive trioxifene.


  • Immunogenic cell death-inducing Rh( i ) and Ir( i ) complexes with bis(imino)acenaphthene-derived ligands: insights into the role of the metal center and the ligands

    by Chengnan Wu, Nikolay Filippovich Romashev, Veronika I. Komlyagina, Tamara Petrović, Ivan V. Bakaev, Pavel A. Abramov, Yuan Wang, Alexey A. Ryadun, Iakov S. Fomenko, Taotao Zou, et al.

    The Rh( i ) complex 3a with the 1,2-bis[(2,6-diisopropylphenyl)imino]acenaphthene (dpp-bian) ligand induces type I immunogenic cell death (ICD), whereas the analogous Ir( i ) complex does not, revealing metal-specific immunogenicity.


  • Open Access

    Ligand supplementation restores the cancer therapy efficacy of the antirheumatic drug auranofin from serum inactivation

    by Yuan Wang, Bei Cao, Qianqian Wang, Sinan Zhong, Xin Fang, Junjian Wang, Albert S. C. Chan, Xiaolin Xiong, Taotao Zou

    Auranofin, an FDA-approved antirheumatic gold drug, has gained ongoing interest in clinical studies for treating advanced or recurrent tumors. However, gold ion's dynamic thiol exchange nature strongly attenuates its bioactivity due to the fast formation of covalent albumin-gold adducts. Here we report that newly-added thiols can modulate the dynamic albumin-gold binding and recover the therapeutic efficacy. Initially, we find that auranofin supplemented with its own thiol ligand, TGTA (1-thio-β-D-glucose tetraacetate), significantly restores the anticancer activities in cells and patient-derived xenograft models. Then, screening a collection of ligand fragments followed by machine learning evaluation unveils diverse synergizing thiols, including pantethine, that effectuate auranofin at a low dosage for rheumatoid arthritis. Interestingly, the thiol exchange inside cells accounts for a cuproptosis-like phenotype that auranofin induces. Together, we believe the ligand-enabled dynamic modulation strategy is of value to researchers and clinicians contemplating metallodrugs and ligand-like molecules in cancer therapy.


  • Oxoisoaporphine Alkaloid Iridium(III) Derivative: An Immunogenic Cell Death Inducer That Engages the Autophagy-Dependent Regulator Cathepsin D

    by Yuan Lu, Feng-Yang Wang, Matthew S. Levine, Hai-Rong Shi, Yuan Wang, Xiaolin Xiong, Liang-Mei Yang, Ya-Qian Shi, Taotao Zou, Jonathan L. Sessler, et al.

    Autophagy has been recognized as one of the pathways for eliciting immunogenic cell death (ICD). However, the specific molecular target responsible for autophagy-mediated ICD has not yet been elucidated. Here, we report that an oxoisoaporphine alkaloid-modified iridium(III) complex (2a) displays autophagy-inducing ICD activity. Through unbiased thermal proteome profiling (TPP), this new complex was found to interact with the lysosomal protease cathepsin D (Cat D). Subsequent cellular and biochemical assays─including the cellular thermal shift assay, isothermal dose-response assay, enzymatic assays, and molecular docking─confirmed that 2a binds to and inhibits Cat D. Further pathway analysis demonstrated that 2a triggers autophagy-dependent ICD via the LKB1-AMPK-ULK1 signaling pathway by inhibiting Cat D. Several other autophagy-dependent ICD inducers were tested and likewise found to inhibit Cat D. In contrast, an earlier reported analogue of 2a, complex 1a, was found to bind and destabilize binding immunoglobulin protein (BiP) and promote its ICD activity through an endoplasmic reticulum stress response. We believe that the findings reported here will enhance the understanding of the novel mechanisms of ICD agents and pave the way for the design of new ICD inducers with high specificity and efficacy.


  • Subcellular Photocatalysis Enables Tumor-Targeted Inhibition of Thioredoxin Reductase I by Organogold(I) Complexes

    by Moyi Liu, Haitao Liu, Yan Yang, Xiaolin Xiong, Taotao Zou

    Selective inhibition of TrxR1 over TrxR2 is a highly sought-after goal, because the two enzymes play distinct roles in cancer progression. However, achieving targeted inhibition is challenging due to their high homology and identical active site sequence. Herein we report a new subcellular photocatalysis approach for targeted inhibition by controllably activating organogold(I) prodrugs within the cytosol, the exclusive location of TrxR1. The NHC-Au(I)-alkynyl complexes are stable and evenly distributed in the cell; they can meanwhile be efficiently transformed into active NHC-Au(I)-L species (L = labile ligands) via a radical mechanism by photocatalysts released into the cytosol (from endosome/lysosome) upon light irradiation, leading to selective inhibition of TrxR1 without affecting TrxR2. This results in strong cytotoxicity to cancer cells with much higher selectivity than auranofin, a pan TrxR inhibitor that cannot discriminate TrxR1/2, along with potent antitumor activities in multiple zebrafish and mouse models. This subcellular prodrug activation may thus suggest a novel approach to precision targeting using the remarkable spatial control of photocatalysis.


  • Recent Advances in the Development of Targeted Activation Strategies for Organoboron Prodrugs

    by Moyi Liu, Taotao Zou

    Elevated levels of reactive oxygen species (ROS) are a hallmark of varieties of diseases such as cancer, inflammation, and neurodegenerative disorders. Inspired by the discrepancy of ROS concentrations between pathological tissues and the normal counterparts, an increasing number of ROS‐responsive theragnostic prodrugs are developed in past years, with particularly high proportions of organoboron‐based prodrugs that can respond to H2O2. Unfortunately, increasing studies have demonstrated that the intrinsic ROS (H2O2) levels in most pathological tissue are only slightly higher than normal tissues and are not adequate to activate organoboron prodrugs; in contrast, several organoboron compounds have been clinically approved in which boronic acid acts as electrophilic warhead. To this end, developing more robust and universal approaches for boronic acid‐prodrug activation becomes highly attractive. In this context, we discuss the recently reported activation strategies for boron‐caged prodrugs with a particular focus on their design principles and activation mechanisms. The perspectives on the future directions for this important research area are discussed as well.


  • Rhodium(III) Complex Noncanonically Potentiates Antitumor Immune Responses by Inhibiting Wnt/β-Catenin Signaling

    by Feng-Yang Wang, Liang-Mei Yang, Xiao-Lin Xiong, Jing Yang, Yan Yang, Jiu-Qin Tang, Lei Gao, Yuan Lu, Yuan Wang, Taotao Zou, et al.

    Metal-based chemoimmunotherapy has recently garnered significant attention for its capacity to stimulate tumor-specific immunity beyond direct cytotoxic effects. Such effects are usually caused by ICD via the activation of DAMP signals. However, metal complexes that can elicit antitumor immune responses other than ICD have not yet been described. Herein, we report that a rhodium complex (Rh-1) triggers potent antitumor immune responses by downregulating Wnt/β-catenin signaling with subsequent activation of T lymphocyte infiltration to the tumor site. The results of mechanistic experiments suggest that ROS accumulation following Rh-1 treatment is a critical trigger of a decrease in β-catenin and enhanced secretion of CCL4, a key mediator of T cell infiltration. Through these properties, Rh-1 exerts a synergistic effect in combination with PD-1 inhibitors against tumor growth in vivo. Taken together, our work describes a promising metal-based antitumor agent with a noncanonical mode of action to sensitize tumor tissues to ICB therapy.